Compare NATL & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATL | MLYS |
|---|---|---|
| Founded | 2023 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.4B |
| IPO Year | 2023 | 2023 |
| Metric | NATL | MLYS |
|---|---|---|
| Price | $47.99 | $28.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $42.28 | ★ $47.33 |
| AVG Volume (30 Days) | 870.1K | ★ 994.8K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.98 | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | ★ $4,354,000,000.00 | N/A |
| Revenue This Year | $5.99 | N/A |
| Revenue Next Year | $4.53 | N/A |
| P/E Ratio | $22.58 | ★ N/A |
| Revenue Growth | ★ 0.86 | N/A |
| 52 Week Low | $22.30 | $9.69 |
| 52 Week High | $48.40 | $47.65 |
| Indicator | NATL | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 76.92 | 41.76 |
| Support Level | $35.19 | $26.85 |
| Resistance Level | N/A | $30.05 |
| Average True Range (ATR) | 1.93 | 1.46 |
| MACD | 0.67 | 0.24 |
| Stochastic Oscillator | 97.03 | 40.98 |
NCR Atleos Corp is financial technology company providing self-directed banking solutions to a customer base including financial institutions, merchants, manufacturers, retailers and consumers. Self-directed banking is a rapidly growing, secular trend that allows banking customers to transact seamlessly between various channels all for the same transaction. Their comprehensive solutions enable the acceleration of self-directed banking through ATM and interactive teller machine (ITM) technology, including software, services, hardware and its proprietary Allpoint network. Atleos manage its operations in the following segments which includes Self-Service Banking, Network, and Telecommunications abd Technology.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.